Junshi Biotech (688180.SH) released semi-annual results with a net loss of 645 million yuan, a year-on-year narrowing

According to Zhitong Finance App News, Junshi Biotech (688180.SH) disclosed its 2024 semi-annual report. During the reporting period, the company achieved revenue of 786 million yuan, an increase of 17.37%; net profit loss to mother was 645 million yuan, a year-on-year narrowing; after deducting non-net profit loss of 627 million yuan, a year-on-year narrowing; and basic earnings per share were -0.65 yuan.

Revenue increased by about $116 million, or 17.37%, over the same period last year, mainly due to the increase in sales revenue of commercial drugs compared to the same period last year. Among them, Tuoyi® achieved sales revenue of RMB 671 million in the domestic market, an increase of about 50% over the previous year.

Net profit attributable to shareholders of listed companies, net profit attributable to shareholders of listed companies, basic earnings per share, diluted earnings per share, and basic earnings per share after deducting non-recurring profit and loss decreased compared to the same period of the previous year, and the proportion of R&D investment in operating income decreased compared to the same period of the previous year. Sales revenue of mainly commercial drugs increased compared to the same period last year. At the same time, as multiple clinical trials of the company's core product Tuoyi® reached major research endpoints and the implementation of the “Improve Quality and Efficiency Potential Return” action plan, the company focused resources on R&D projects with more capacity. floor, Technical service fees and employee remuneration were reduced accordingly, leading to a reduction in losses.